|
WO2021046404A1
|
|
Method for increasing lymphocyte count by using il-7 fusion protein in tumors
|
|
WO2020184941A1
|
|
Glp-1 fusion proteins and uses thereof
|
|
KR20190093165A
|
|
Composition for promoting stability of Fusion Polypeptide Comprising GLP-1 and Immunoglobulin Hybrid Fc
|
|
KR20180119135A
|
|
4-1bbl variant and fused protein comprising same
|
|
US2019224281A1
|
|
PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN
|
|
WO2018044060A1
|
|
PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN
|
|
CA3014164A1
|
|
Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
|
|
WO2017142331A1
|
|
Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
|
|
TW201729829A
|
|
Pharmaceutical composition for the prevention or treatment of human papillomavirus-related diseases comprising immunoglobulin Fc-fused interleukin-7
|
|
KR20170066255A
|
|
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLUENZA VIRUS INFECTION COMPRISING IMMUNOGLOBULIN Fc-FUSED INTERLEUKIN-7
|
|
KR20180050179A
|
|
Modified pd-l1 protein and use thereof
|
|
WO2017069401A1
|
|
Composition for alleviating skin wrinkles
|
|
WO2016200219A1
|
|
Modified interleukin-7 protein and uses thereof
|
|
CN107427554A
|
|
Use the method for long-acting EPO formulations treatment anaemia
|
|
KR20160083810A
|
|
Fusion Polypeptide Comprising GLP and Immunoglobulin Hybrid Fc and use thereof
|
|
KR20170053511A
|
|
Formulation for modified interleukin-7 fusion protein
|
|
TW201716445A
|
|
Immunoglobulin fusion proteins
|
|
TW201714894A
|
|
Immunoglobulin fusion proteins
|
|
US2016108105A1
|
|
Human igg4 fc polypeptide variant
|
|
CA2957128A1
|
|
Methods of treating cervical cancer
|
